Prothena Corporation

PRTA | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.51

-$0.07 (-0.82%)

At close: Sep 21, 2026, 4:00 PM ET

$8.75

+$0.24 (+2.82%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.82%

(1D)

Rating

Updated: Aug 13, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $445.53M

1D Range

8.48 8.80

52W Range

7.73 11.80

Valuation (TTM)

PE -10.13

PB 1.55

EV/EBITDA -3.99

Valuation (NTM)

Forward PE 310.33

Forward PEG 0.01

Price Target $30

Cash Flow

FCF Yield -7.2%

SBC Adj. FCF Yield -15.2%

SBC Impact -113.0%

Margins

Gross Margin 43.5%

Operating Margin -115.1%

FCF Margin -58.4%

Growth (CAGR)

Revenue 3Y | 5Y -1.8% | -2.1%

Dil EPS 3Y | 5Y 3.2% | -19.4%

FCF 3Y | 5Y 31.8% | -18.2%

Returns

ROA -14.5%

ROE -15.0%

ROIC -21.4%

Financial Health

Net Cash

$281.2M

Current Ratio 25.05

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline i...

Sector Healthcare

Industry Biotechnology

Employees 67

IPO Date Dec 19, 2012

Website www.prothena.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$30

Upside

+252.53%

Buy (3)

Hold (1)

Sell (0)

Analyst Details ➞